ENGLISH IMP ARTICLE imp for IBPS RRB OFFICER SCALE 1
In August 2014, the World Health Organization declared the epidemic of Ebola virus disease (EVD) in West Africa as a public health emergency of international concern. This was the first in more than 20 outbreaks since EVD was identified in 1976 that such a declaration was made.1 pandemic, combined all previous EVD outbreaks have accounted for more cases of EVD 28,616 cases and 11,310 people With the death of 2. reported, the majority of the 3 cases, Guinea, Liberia, and other western African countries in Sierra Leone, with a small number of cases, 4 Europe, and the United States States.5 last EVD. While crossing, it was controlled by the implementation of strategies for identification of segregation of cases, segregation of case patients, and contact tracing, the scope of the epidemic and the period explained the importance of establishing additional preventive devices such as an effective vaccine.
Ebola virus is a 19-kb, a phytovirus with non-fragmented, negative-stranded RNA genomes, which encodes seven viral proteins. Surface glycoprotein mediates viral penetration in host cells 7,8 and has been the primary antigenic target for vaccine development. 9 A series of gene-based approach to developing Ebola vaccine in the first Ebola challenge study involving Ebola vaccine with non-primates, 10-12 and three early generation candidates, we have previously evaluated because 2003 and 2009 of the worsened theoretical security concerns were included. Between -15 was evaluated in clinical trials, Ebola glycoprotein cytothheid effects in cell culture, 7 Early Antigens Dies Tronsmemebran-deleted version of the glycoprotein 13 Inon and a full-length glycoprotein antigen which includes an amino acid mutation. 14 No safety concerns were identified from these vaccines, but advanced development did not follow because immunogenicity and post-preclinical efficacy results were considered inadequate. Therefore, full-length wild-type glycoprotein distributed by DNA vaccination was evaluated clinically and it was shown immunogenic. 15 These figures supported the accelerated development of the chimpanzee adenovirus type 3 (CAD3) vaccine vector described here, that wild type Glycoprotein Zaire and Sudan species from Ebolaivirus
CAD3 Ebola Vaccine (CAD-3-EBO) is based on the performance of clinical development based on the performance of significant efficacy in a non-primitive challenge challenge model of low-level antioxidant antibody 5 weeks in 10 months of non-injection and partial efficacy. Was chosen for. In addition to the human population, cAd3-EBO recombinant modified chickpeas with Ankara (MVA), a boost wild type glycoprotein vaccine, which results in more durable protection than challenges at 10 months.16 non-primate primes
Clinical development of the CAD 3-EBO Vaccine began in 2011; In response to the emerging outbreak in a former investigative New Drug Application (former IND), the Food and Drug Administration (FDA) was introduced in 2013, and for the first quarter of 2015 though a Phase 1 clinical trial was scheduled for May In 2014, we started CAD 3-EBO Phase 1 Clinical Test, working closely with FDA and conducting standard scheduling. In November 2014, we reported the initial safety and immunization alternatives of the vaccine. Here we report the updated results, including results in regards to the long-term stability of the cAd3-EBO vaccine in healthy adults.